Hospira Recalls Contaminated Painkiller

The Wall Street Journal (2/12, Loftus, Subscription Publication, 5.67M) reported that Hospira, the manufacturer of a widely-used generic painkiller in hospitals, recalled over 60 lots of vials as a result of contamination by calcium-ketorolac crystals. Hospira said the contamination could cause side effects but that none have been reported. Hospira produces 95% of the ketorolac distributed in the US, so the recall has caused a shortage of the drug. The company is investigating the cause of the contamination.


GM To Temporarily Stop Selling Some SUVs Due To Pending Goodyear Tire Recall

The Detroit Free Press (1/22, Priddle, 987K) reported that General Motors told dealers to stop selling 2015 Chevrolet Traverse, GMC Acadia and Buick Enclave utility vehicles due to a pending recall of the 18-inch tires on the 6,300. The article states that Goodyear is working with the NHTSA and expects recall 48,500 tires, “of which about 32,100 were made for GM’s family of full-size crossovers.”


Medtronic Will Pay $2.8 Million To Settle Allegations Of Encouraging Off-Label Use Of Device To Doctors

Law 360 (2/6, Macagnone, 9K) is reporting that Medtronic will settle with the US Justice Department for $2.8 million regarding a False Claims Act Suit contending the company “paid doctors to push an unapproved use” of the company’s neuro-stimulation device, “SubQ stimulation treatment.” The Justice Department has accused Medtronic of paying out “tens of thousands of dollars” to urge physicians to make an off-label use of the device, and to seek Medicare payments for treatments “not approved by the U.S. Food and Drug Administration.”


More Pre-Market Testing of Vaginal Mesh Products is Needed

An FDA Advisory Panel recommended on September 9, 2011, that vaginal mesh products be reclassified to Class III devices and that more stringent pre-market testing be required before approval.  Class III devices are required to undergo full pre-market approval, including safety
testing.  Special Controls can be instituted such as physician labeling, patient labeling, pre-market studies, performance standards, patient registry, and importantly, enhanced post market surveillance.  Most mesh products are exempt from pre-market testing.  Mesh products are approved under 510(k) review which only requires a showing that a device is substantially similar to another device previously approved.

Transvaginal mesh products are used to repair conditions in women such as pelvic organ prolapsed (POP) and stress urinary incontinence (SUI).  Pelvic organ prolapsed is the bulge of organs/structures surrounding the vagina into the vaginal opening or extending beyond the vaginal opening, caused by a laxity of supporting tissue of the vagina.  Stress Urinary Incontinence is the involuntary leaking of urine associated with an increase in intraabdominal pressure which may be caused by straining, physical activity, coughing or sneezing.

From 1992 until 2010, the FDA approved 168 vaginal mesh devices used for repair of POP or SUI.  These products were approved using
the 510(k) process and they did not undergo preclinical testing.  Most of these devices were approved between 2001 and 2010.  Serious complications associated with surgical mesh for vaginal repair of pelvic organ prolapsed and stress urinary incontinence have increased dramatically along with the flood of additional mesh devices onto the market. From 2008 until 2010, nearly 3,000 adverse events have been associated with surgical repair of POP and SUI using the transvaginal placement of mesh.  These adverse events include organ perforation, bleeding, urinary incontinence, fecal incontinence, pelvic pain, infection, discomfort during intercourse, and the need for corrective surgeries.

If you or someone you love has suffered from Transvaginal Mesh Products, contact Boyd B.Newton.  Boyd B. Newton is a prominent Atlanta Product Liability Attorney with the knowledge and experience to help.